{
  "id": "5c58a0e486df2b917400000c",
  "type": "summary",
  "question": "What is the mechanism of action of Ivosidenib?",
  "ideal_answer": "Ivosidenib is an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models. It is effective for IDH1-mutant relapsed/refractory acute myeloid leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29266015",
    "http://www.ncbi.nlm.nih.gov/pubmed/29950729",
    "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
    "http://www.ncbi.nlm.nih.gov/pubmed/30466743",
    "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
    "http://www.ncbi.nlm.nih.gov/pubmed/30209701",
    "http://www.ncbi.nlm.nih.gov/pubmed/30093505",
    "http://www.ncbi.nlm.nih.gov/pubmed/29934313"
  ],
  "snippets": [
    {
      "text": " Finally, targeted agents inhibiting multiple kinases (rigosertib), BCL2 (venetoclax) or mutant IDH1 (ivosidenib), IDH2 (enasidenib), FLT3 (sorafenib, midostaurin) or spliceosome components (H3B-8800) are other novel options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29266015",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29670690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase I study suggests that ivosidenib can induce remission in patients with relapsed or refractory acute myeloid leukemia characterized by IDH1 mutations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29934313",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.METHODS: We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biochemical studies predicted that resistance to allosteric IDH inhibitors could also occur via IDH dimer-interface mutations in cis, which was confirmed in a patient with acquired resistance to the IDH1 inhibitor ivosidenib (AG-120). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29950729",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA approved ivosidenib for patients with IDH1-mutant relapsed/refractory acute myeloid leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30093505",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.<br><b>METHODS</b>: We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29860938",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}